申请人:MERIT THERAPEUTICS INC
公开号:WO2022159506A1
公开(公告)日:2022-07-28
This invention relates to deuterated cannabidiol compounds, methods for preparation thereof, compositions comprising the same, uses thereof, and methods comprising administration of deuterated cannabidiol compounds and at least one additional therapeutic agent, for the treatment or prevention of diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, aggression, fear, phobias, anxiety, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
本发明涉及氘代大麻二酚化合物、其制备方法、包含其的组合物、使用方法以及包括氘代大麻二酚化合物和至少一种额外治疗剂的方法,用于治疗或预防疾病或疾病,包括但不限于脆性X综合症、自闭症谱系障碍、溶酶体贮存病、白质脑病、雷特综合症、骨关节炎、肌肉骨骼疾病、厌食症、恶心、疼痛、炎症、多发性硬化症、神经退行性疾病(帕金森病、亨廷顿病、阿尔茨海默病)、癫痫、攻击性、恐惧症、焦虑症、青光眼、骨质疏松症、精神分裂症、心血管疾病、癌症、肥胖症和代谢综合征相关疾病。